TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05205278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: The core stability training programme was performed 3 days per week over an 8-week period, and each training session lasted approximately 50 minutes.We created a special programme for our study based on the literature; the core stability training programme was divided into 3 phases: easy(1-2 weeks), moderate(3-5 weeks) and difficult(6-8 weeks In the easy phase(phase1), the athlete was intended to gain sensorimotor control that would ensure the smoothness of the neutral spine during slow movements. The participants learned the hallowing technique and how to use this technique while doing core exercises. In the moderate phase(phase2), muscular neural adaptation and neuromuscular facilitation were targeted with the transition to high threshold strength training.In the last, difficult, phase(phase3), subconscious control of movement was taught using combined movement patterns with the aim of transitioning to functional positions and activities.
Study: NCT01091051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Soduim Chloride)
Description: Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
Study: NCT02277340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EAPA
Description: Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
Study: NCT03771690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardised meal
Description: A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardised meal
Description: A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
Study: NCT01799304

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no distractor control group
Description: This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: visual and sound attentional distractors
Description: The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sound attentional distractor alone
Description: In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: additional cognitive task
Description: The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
Study: NCT00503737

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National Colorectal Cancer Roundtable Toolbox
Study: NCT03944083

Intervention type: OTHER
Intervention: Treatment as usual for ADHD
Description: Children are given treatment according to diagnostic conclusion and clinical recommendations.
Study: NCT03760276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole Oral Product (Vfend®)
Description: To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
Study: NCT03235375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously
Study: NCT02600494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007 (Lumateperone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007 (Lumateperone)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03285906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Targeted therapy Apatinib：500 mg，po，qd
Study: NCT03579225

Intervention type: DEVICE
Intervention: MATRx plus test
Description: The MATRx plus is a home-based test that allows the healthcare provider to determine if a patient with obstructive sleep apnea will benefit from oral appliance therapy. Prior to the test, a dentist fits the patient with dental trays and measures the patient's comfortable jaw range of motion. The trays are connected to a mandibular positioner. During sleep, the device collects airflow from a nasal cannula and blood oxygen saturation from a pulse oximeter. These signals are used by the device software to control the mandibular positioner and protrude the mandible. During the test, the device moves the lower jaw within the patient's range of motion to predict if the patient is likely to benefit from oral appliance therapy and, if so, the appropriate amount of protrusion. Additional study nights may be required if the data from either of the first two nights are insufficient or if a more precise determination of the amount of jaw protrusion that provided a therapeutic benefit can be made.
Study: NCT02591238

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-smoker oral placebo
Description: Participants oral placebo last 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-smoker oral melatonin
Description: Participants oral melatonin 3 mg/day last 2 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: smoker oral placebo
Description: Participants oral placebo last 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: smoker oral melatonin
Description: Participants oral melatonin 3 mg/day last 2 weeks.
Study: NCT03015558

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session
Description: transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session
Description: transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation of opercular-insular cortex - active control session
Description: transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation of opercular-insular cortex - active control session
Description: transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation of opercular-insular cortex - sham control session.
Description: transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation of opercular-insular cortex - sham control session.
Description: transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
Study: NCT01525940

Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam Colon Capsule Endoscopy (Given® Diagnostic System)
Description: 2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
Study: NCT03293628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Packing
Description: This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Packing
Description: This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
Study: NCT03585673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PM
Description: Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression
Study: NCT03917225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-102
Description: Once-daily dosing with a volume specified by the pharmacokinetic specialist to achieve the desired plasma exposure. MIN-102 oral suspension, strength 15 mg/ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral suspension.
Study: NCT02911623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Lithoplasty® System
Description: The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
Study: NCT02297737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Study: NCT02073903

Intervention type: BEHAVIORAL
Intervention: Patient Survey

Intervention type: BEHAVIORAL
Intervention: Provider Survey
Study: NCT03487406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: One 90 mg tablet, oral, twice daily for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: One 90 mg tablet, oral, twice daily for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: One 75 mg tablet, oral, once a day, for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: One 75 mg tablet, oral, once a day, for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Aspirin
Description: Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Aspirin
Description: Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ticagrelor
Description: Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ticagrelor
Description: Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
Study: NCT03125577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR22
Description: 4SCAR19 and 4SCAR22

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR38
Description: 4SCAR19 and 4SCAR38

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR20
Description: 4SCAR19 and 4SCAR20

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR123
Description: 4SCAR19 and 4SCAR123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR70
Description: 4SCAR19 and 4SCAR70
Study: NCT00354341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin beta
Study: NCT04525638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate
Description: 7.4 GBq 177Lu-DOTATATE intravenously as a 4-hours infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg flat dose of nivolumab intravenously as a 30-minutes infusion
Study: NCT00070057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02440568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine (100mg/m\^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine (100mg/m\^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
Study: NCT01024348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extended-release tramadol
Description: 30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
Study: NCT02440568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine (100mg/m\^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine (100mg/m\^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin (12 mg/m\^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin (12 mg/m\^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin (12 mg/m\^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Idarubicin (12 mg/m\^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 0.625mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 1.25mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 2.0mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine mepesuccinate
Description: Omacetaxine administered subcutaneously Q12 hours Days 1 to 7. Dose level 3.0mg/m\^2
Study: NCT04928274

Intervention type: OTHER
Group type: OTHER
Intervention: ball attachment to retain mandibular over denture
Description: each patient in group receive 3 locator attachment for over denture retention

Intervention type: OTHER
Group type: OTHER
Intervention: locator attachment to retain mandibular over denture
Description: each patient in group receive 3 locator attachment for over denture retention

Intervention type: OTHER
Group type: OTHER
Intervention: telescopic attachment to retain mandibular over denture
Description: each patient in group receive 3 telescopic attachment for over denture retention
Study: NCT03125577

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR19 and 4SCAR30
Description: 4SCAR19 and 4SCAR30
Study: NCT01585493

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care coordinator
Description: Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
Study: NCT01024348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
Study: NCT05135598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partners for Life health behavior change program
Description: A health behavior change intervention based on partner learning, utilizing low-tech media and a workbook.
Study: NCT01302327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide
Study: NCT01585493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHANGE
Description: Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.~CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change.
Study: NCT00233506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG 7909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG 7909
Study: NCT03500653

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 4 gr curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 gr placebo
Study: NCT02148341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community of Practice Facilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Study: NCT01002014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nipple Sparing Mastectomy
Description: Skin sparing mastectomy with preservation of the nipple areolar complex
Study: NCT01700166

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Cord Blood derived Stem Cell injection
Description: One time intravenous (in the vein) injection with two year follow-up
Study: NCT01212029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral measures
Description: Behavioral tasks/ questionnaires

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fNIRS Devices &amp; Application
Description: Device 1- fNIRSoft and Device 2 - NIRScout
Study: NCT03509987

Intervention type: DEVICE
Group type: OTHER
Intervention: HemaCue
Description: comparing hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.
Study: NCT01924299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT01212029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological measures
Description: A set of tasks.
Study: NCT01924299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Administered orally